Johnson & Johnson’s ICOTYDE Shows 49% PASI100 Clearance at Week 52
ICOTYDE’s PASI100 rates rose from 41% to 49% in ADVANCE 1 and from 33% to 48% in ADVANCE 2 between Weeks 24 and 52, with placebo-switched patients reaching 50% and 43% clearance. In adolescents, 57% achieved PASI100 and 86% PASI90 at one year with no new safety signals.
1. Phase 3 Efficacy Results
ICOTYDE’s Phase 3 ADVANCE 1 and 2 trials showed PASI100 clearance rates rising from 41% to 49% and from 33% to 48%, respectively, between Week 24 and Week 52. Patients switching from placebo at Week 16 achieved similar clearance rates of 50% in ADVANCE 1 and 43% in ADVANCE 2 by Week 52.
2. Adolescent Outcomes in ICONIC-LEAD
In the ICONIC-LEAD study, adolescent patients reached 57% complete clearance (PASI100) and 61% IGA0 at Week 52, with 86% achieving PASI90 and 92% maintaining that response from Week 24 to Week 52. No new safety signals emerged over one year of treatment.
3. Safety Profile and Competitive Position
Over 52 weeks, ICOTYDE maintained a favorable safety profile with stable adverse event rates and lower infection rates through Week 24 than deucravacitinib. The once-daily oral peptide IL-23 receptor blocker showed no new safety signals.
4. Commercial and Regulatory Outlook
As the first targeted oral IL-23R blocker for moderate-to-severe plaque psoriasis, ICOTYDE’s robust one-year data support its positioning as a first-line systemic therapy. These results pave the way for regulatory filings and potential launches in adult and adolescent psoriasis indications.